15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Bicycle Therapeutics Ltd, 4 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $7.00 to $36.00 (about 5.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $14.00 sits 254% above the current $3.96. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.52 next quarter toward $-2.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy457%
Hold343%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Bicycle Therapeutics Ltd.
As of Jul, 4 of 7 firms rate BCYC a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCYC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-0.66 – $-0.37 · 8 analysts · -39% YoY
Next period, 8 analysts expect Bicycle Therapeutics Ltd to earn $-0.52 a share (range $-0.66 – $-0.37), versus $-0.85 a year earlier. Full-year consensus is $-2.32, growing to $-2.19 the year after.
REVENUE · NEXT QUARTER
$4.1M
Range $758.0K – $10.0M · 8 analysts · -65% YoY
Revenue is expected to reach $4.1M (range $758.0K – $10.0M), -65.1% year-over-year. Full-year consensus is $17.1M, rising to $15.5M next year.
Top analysts covering Bicycle Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCYC.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Hold
$12.00+203.4% to target
Overall win rate
61%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #69
Hold
$5.00+26.4% to target
Overall win rate
42%
+ Follow
#3
Ami Fadia
Needham · Rank #90
Buy
$15.00+279.3% to target
Overall win rate
46%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #179
Buy
$32.00+709.1% to target
Overall win rate
34%
+ Follow
#5
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$33.00+734.4% to target
Overall win rate
37%
+ Follow
BCYC stock forecast FAQ
What is BCYC's average 12-month price target?+
The 7 analysts with a live target average $14.00 for Bicycle Therapeutics Ltd over the next 12 months, ranging from a $36.00 high to a $7.00 low.
Is BCYC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 4 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BCYC?+
The Street-high target is $36.00 (Oppenheimer), and the Street-low is $7.00 (RBC Capital). The average of all 7 active targets is $14.00.
How many Wall Street analysts cover BCYC?+
7 analysts have an active rating on Bicycle Therapeutics Ltd, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering BCYC?+
Among analysts who currently cover BCYC, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Hold with a $12.00 target.
What is Bicycle Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-0.66 – $-0.37) across 8 analysts. Full-year EPS is projected at $-2.32, rising to $-2.19 the following year.
How much revenue is Bicycle Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $4.1M (range $758.0K – $10.0M). Full-year revenue is projected at $17.1M, growing to $15.5M next year.
Have analysts been upgrading or downgrading BCYC lately?+
As of Jul, 4 of 7 firms rate BCYC a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCYC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
